Hitting the target in IDH2 mutant AML

被引：3
|
作者：
Wouters, Bas J. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
来源：
BLOOD | 2017年 / 130卷 / 06期
关键词：
DIFFERENTIATION; LEUKEMIA; CELLS;
D O I：
10.1182/blood-2017-06-790394
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Stein et al(1) demonstrate the feasibility and clinical efficacy of targeted inhibition of mutant isocitrate dehydrogenase 2 (IDH2) in patients with acute myeloid leukemia (AML). In a related paper, Amatangelo et al(2) investigate mechanisms of response in samples derived from the same patients.
引用
收藏
页码：693 / 694
页数：2
相关论文
共 50 条
  • [41] Clinical Validation of Mutant IDH1 and IDH2 Detection by Multiplex Digital Droplet PCR
    Racchumi, J.
    Kluk, M.
    Al-Ghamdi, Y.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S24 - S24
  • [42] Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group
    Nomdedeu, J.
    Hoyos, M.
    Carricondo, M.
    Esteve, J.
    Bussaglia, E.
    Estivill, C.
    Ribera, J. M.
    Duarte, R.
    Salamero, O.
    Gallardo, D.
    Pedro, C.
    Aventin, A.
    Brunet, S.
    Sierra, J.
    LEUKEMIA RESEARCH, 2012, 36 (08) : 990 - 997
  • [43] The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies
    Thota, Swapna
    Makishima, Hideki
    Przychodzen, Bartlomiej P.
    Viny, Aaron D.
    Patel, Bhumika J.
    Radivoyevitch, Tomas
    Sekeres, Mikkael A.
    Carraway, Hetty E.
    Haferlach, Torsten
    Ogawa, Seishi
    Maciejewski, Jaroslaw P.
    BLOOD, 2014, 124 (21)
  • [44] A new era after a long wait: Vorasetinib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma
    Silvani, Antonio
    Franceschi, Enrico
    TUMORI JOURNAL, 2024, 110 (03): : 160 - 161
  • [45] Hitting the target in HER2 mutant cancers
    Katayama, Ryohei
    NATURE CANCER, 2022, 3 (07) : 785 - 786
  • [46] Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups
    Damm, F.
    Thol, F.
    Hollink, I.
    Zimmermann, M.
    Reinhardt, K.
    van den Heuvel-Eibrink, M. M.
    Zwaan, C. M.
    de Haas, V.
    Creutzig, U.
    Klusmann, J-H
    Krauter, J.
    Heuser, M.
    Ganser, A.
    Reinhardt, D.
    Thiede, C.
    LEUKEMIA, 2011, 25 (11) : 1704 - 1710
  • [47] Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
    Wang, Fang
    Travins, Jeremy
    DeLaBarre, Byron
    Penard-Lacronique, Virginie
    Schalm, Stefanie
    Hansen, Erica
    Straley, Kimberly
    Kernytsky, Andrew
    Liu, Wei
    Gliser, Camelia
    Yang, Hua
    Gross, Stefan
    Artin, Erin
    Saada, Veronique
    Mylonas, Elena
    Quivoron, Cyril
    Popovici-Muller, Janeta
    Saunders, Jeffrey O.
    Salituro, Francesco G.
    Yan, Shunqi
    Murray, Stuart
    Wei, Wentao
    Gao, Yi
    Dang, Lenny
    Dorsch, Marion
    Agresta, Sam
    Schenkein, David P.
    Biller, Scott A.
    Su, Shinsan M.
    de Botton, Stephane
    Yen, Katharine E.
    SCIENCE, 2013, 340 (6132) : 622 - 626
  • [48] Hitting the target in HER2 mutant cancers
    Ryohei Katayama
    Nature Cancer, 2022, 3 : 785 - 786
  • [49] ARE MUTATIONS IN THE IDH2 GENE SUITABLE MOLECULAR MARKERS FOR MRD MONITORING IN AML PATIENTS?
    Jeziskova, I.
    Razga, F.
    Dvorakova, D.
    Semerad, L.
    Sustkova, Z.
    Mayer, J.
    Racil, Z.
    HAEMATOLOGICA, 2013, 98 : 510 - 510
  • [50] Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
    Kats, Lev M.
    Reschke, Markus
    Taulli, Riccardo
    Pozdnyakova, Olga
    Burgess, Kerri
    Bhargava, Parul
    Straley, Kimberly
    Karnik, Rahul
    Meissner, Alexander
    Small, Donald
    Su, Shinsan M.
    Yen, Katharine
    Zhang, Jiangwen
    Pandolfi, Pier Paolo
    CELL STEM CELL, 2014, 14 (03) : 329 - 341
12345